Previously, we identified MerTK as a cell intrinsic therapeutic target, given that its expression on leukemia cells confers a survival advantage and chemoresistance in vitro and in vivo (16–19). These discoveries led to the development of type 1 MerTK small molecule inhibitors, including MRX2843, which is currently being tested in early phase clinical trials (NCT03510104, NCT04872478, NCT04762199) for its inhibitory effects on MerTK and FLT3. The gene discussed is MERTK; the disease is leukemia.